DE69329558D1 - Verfahren zur Behandlung von Multiplesklerose - Google Patents

Verfahren zur Behandlung von Multiplesklerose

Info

Publication number
DE69329558D1
DE69329558D1 DE69329558T DE69329558T DE69329558D1 DE 69329558 D1 DE69329558 D1 DE 69329558D1 DE 69329558 T DE69329558 T DE 69329558T DE 69329558 T DE69329558 T DE 69329558T DE 69329558 D1 DE69329558 D1 DE 69329558D1
Authority
DE
Germany
Prior art keywords
necrosis factor
tumour necrosis
multiple sclerosis
procedure
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69329558T
Other languages
English (en)
Other versions
DE69329558T2 (de
Inventor
Leslie Turk
David Baker
Marc Feldmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kennedy Trust for Rheumatology Research
Original Assignee
Kennedy Institute of Rheumotology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kennedy Institute of Rheumotology filed Critical Kennedy Institute of Rheumotology
Application granted granted Critical
Publication of DE69329558D1 publication Critical patent/DE69329558D1/de
Publication of DE69329558T2 publication Critical patent/DE69329558T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preliminary Treatment Of Fibers (AREA)
  • Transplanting Machines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Spinning Or Twisting Of Yarns (AREA)
  • Treatment Of Fiber Materials (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69329558T 1993-07-30 1993-07-30 Verfahren zur Behandlung von Multiplesklerose Expired - Lifetime DE69329558T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB1993/001614 WO1995003827A1 (en) 1993-07-30 1993-07-30 Method for treating multiple sclerosis

Publications (2)

Publication Number Publication Date
DE69329558D1 true DE69329558D1 (de) 2000-11-16
DE69329558T2 DE69329558T2 (de) 2001-05-31

Family

ID=10729416

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69329558T Expired - Lifetime DE69329558T2 (de) 1993-07-30 1993-07-30 Verfahren zur Behandlung von Multiplesklerose

Country Status (11)

Country Link
US (1) US5958409A (de)
EP (2) EP1004312A1 (de)
JP (1) JPH09509646A (de)
AT (1) ATE196849T1 (de)
AU (1) AU4719093A (de)
DE (1) DE69329558T2 (de)
DK (1) DK0710121T3 (de)
ES (1) ES2153384T3 (de)
GR (1) GR3035196T3 (de)
PT (1) PT710121E (de)
WO (1) WO1995003827A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US7070783B1 (en) * 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
US7012060B1 (en) 1995-07-14 2006-03-14 Applied Research Systems Ars Holding N.V. TNF receptor and steroid hormone in a combined therapy
EP0839046B1 (de) * 1995-07-14 2002-01-23 Applied Research Systems ARS Holding N.V. Tnf-rezeptor und steroidhormon dhea in einer kombinationstherapie
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
US6982089B2 (en) * 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
USRE45976E1 (en) * 1999-02-24 2016-04-19 Tact Ip, Llc Methods of inhibiting the action of TNF for neurological conditions by administering etanercept intrathecally
US8119127B2 (en) * 1999-02-24 2012-02-21 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
AU6929100A (en) * 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
CN101653604A (zh) * 2001-05-30 2010-02-24 基因技术股份有限公司 抗ngf抗体用于治疗各种疾病
US20050175585A1 (en) * 2001-06-11 2005-08-11 Transition Therapeutics Inc. Combination therapies using vitamin B12 and interferon for treatment of viral proliferative and inflammatory disesases
JP2004536819A (ja) * 2001-06-11 2004-12-09 トランジション・セラピューティックス・インコーポレーテッド ウイルス性、増殖性および炎症性の疾患の治療のためにビタミンｂ１２および治療薬を用いた複合治療
BR0307727A (pt) * 2002-02-20 2005-01-25 Lilly Co Eli Fomulação
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
WO2004050683A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
US8236306B2 (en) * 2004-12-18 2012-08-07 Edward Lewis Tobinick Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
US20080317710A1 (en) * 2006-02-22 2008-12-25 University Of Zurich Methods For Treating Autoimmune or Demyelinating Diseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
SG11201507371RA (en) 2013-03-14 2015-10-29 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various deseases
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
EP0486526B2 (de) * 1989-08-07 2001-03-07 Peptech Limited Bindeligande für tumornekrosisfaktor
EP1132471A3 (de) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
DE4202665A1 (de) * 1992-01-28 1993-07-29 Schering Ag Prostacyclin- und carbacyclinderivate als mittel zur behandlung von multipler sklerose

Also Published As

Publication number Publication date
US5958409A (en) 1999-09-28
DE69329558T2 (de) 2001-05-31
GR3035196T3 (en) 2001-04-30
EP0710121A1 (de) 1996-05-08
WO1995003827A1 (en) 1995-02-09
EP0710121B1 (de) 2000-10-11
JPH09509646A (ja) 1997-09-30
ES2153384T3 (es) 2001-03-01
AU4719093A (en) 1995-02-28
PT710121E (pt) 2001-04-30
DK0710121T3 (da) 2001-02-05
EP1004312A1 (de) 2000-05-31
ATE196849T1 (de) 2000-10-15

Similar Documents

Publication Publication Date Title
DE69329558D1 (de) Verfahren zur Behandlung von Multiplesklerose
DE3856398D1 (de) Verfahren zur Behandlung von Gleitkörpern
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE69435270D1 (de) Verwendung der neurotoxischen Komponente von Botulinum Toxin zur Behandlung spastischer Muskeln
PT646012E (pt) Cura de feridas e tratamento de perturbacoes fibroticas por tgfbeta-3
ATE247974T1 (de) Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
NO941780D0 (no) Fremgangsmåte for behandling av TNF-avhengig inflammasjon under anvendelse av tumornekrosefaktorantagonister
NO901141L (no) Additiv og fremgangsmaate for behandling av underjordiske formasjoner.
DK0380230T3 (da) Immunogene sammensætninger mod gastrin-peptider
DE68910175D1 (de) Adsorbermodul sowie Adsorberapparat zur Behandlung von Vollblut.
ATE111519T1 (de) Familie von modifizierten antikörpern mit hoher affinität zur behandlung von krebs.
DE68917433D1 (de) Verfahren zur behandlung von asbest sowie asbestbehandlungsmittel.
DE69327248D1 (de) Verfahren zur behandlung des symptomenkomplexes des prämenstruellen syndroms mit vitamin d oder vitamin d und calcium
DE3381624D1 (de) Mittel zur behandlung von wunden.
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
KR880701558A (ko) 동맥경화증의 치료방법 및 치료용 기질 조성물
DE69220939D1 (de) Gegengift immunsera
ATE100331T1 (de) Verfahren zur behandlung von septischem schock.
ATE202935T1 (de) Verfahren zur behandlung von haarausfall
DE69218200D1 (de) Behandlung von leberkrebs
DE3878529D1 (de) Vorrichtung zur behandlung von verstauchungen, insbesondere der sprunggelenke sowie zur vermeidung von dabei auftretenden bestimmten komplikationen.
DE68909750D1 (de) Vorrichtung zur therapeutischen behandlung von lumbago sowie lumbago/ischias.
DE69232852D1 (de) Verwendung von topotecan in der behandlung von nichtkleinzelligen lungenkarzinomen
DE69131058D1 (de) Verwendung einer therapeutischen Zusammensetzung zur Behandlung von Bronchitis
DE3585312D1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyrido(1,2-a)pyrimidin-3-carboxamid zur vorbeugung und behandlung von gastrointestinalschaeden.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition